SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Eli Lilly's Biotechnology Center in California
Earnings
Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3
Mounjaro and Zepbound contributed more than $10 billion to the $11.98 billion in sales Lilly recorded for key products in the third quarter, despite price decreases for the GLP-1 medicines.
October 30, 2025
 · 
1 min read
 · 
Annalee Armstrong
Investment mistakes, taxes, expenses, and unknown costs drain money, concept of Businessman carries a money bag with a big hole, banknotes falling out
Manufacturing
Lilly Continues Manufacturing Push With $1.2B Puerto Rico Facility for GLP-1 Pill
The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of around 1,000 construction-related roles.
October 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
CAR-T
Kyverna’s CAR T Therapy Sets ‘New Efficacy Standard’ in Myasthenia Gravis, De-Risking Phase III Trials
With a 100% response rate in a Phase II study, KYV-101 sets a new efficacy bar in generalized myasthenia gravis, according to analysts at William Blair.
October 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Regulatory
Life-Threatening Liver Toxicity Triggers FDA Freeze on Two Intellia Gene Therapy Studies
The clinical hold comes days after Intellia voluntarily paused enrollment and dosing in the same two studies.
October 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Vector illustration of two businessmen engaged in a hand wrestling match, symbolizing competition, rivalry, power struggles, competitive environments, and conflict resolution concepts
Mergers & acquisitions
UPDATE: Novo Nordisk Seeks To Steal Metsera From Pfizer With $8.5B Offer
Pfizer called Novo’s offer “reckless and unprecedented,” in a statement issued Thursday morning.
October 30, 2025
 · 
4 min read
 · 
Annalee Armstrong
Illustration of arrow pointing down, away on top of U.S. flag
Job Trends
Almost 1/3 Eyeing Job Options Outside US, BioSpace Finds
Nearly one-third of biotech and pharma professionals are thinking about leaving the U.S. to find biopharma jobs, according to a BioSpace LinkedIn poll. Career coaches discuss why people are considering relocating and what they should do before heading for the exit.
October 30, 2025
 · 
4 min read
 · 
Angela Gabriel
Photo of Hudson Yards skyscrapers in Midtown Manhattan, New York
Job Trends
8 Companies Hiring Now in New York
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
October 30, 2025
 · 
2 min read
 · 
Angela Gabriel
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
Biosimilars
FDA Proposes Lower Bar for Biosimilar Approvals in Bid To Lower Drug Prices
Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, HHS leaders said while announcing new draft guidance.
October 29, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Dorval, Quebec, Canada - September 3, 2021: Novartis Pharmaceuticals Canada Inc. head office building in Dorval, Quebec, Canada. Novartis is a global healthcare company based in Switzerland.
Immunology and inflammation
Novartis Presents New Data From Potential First Targeted Sjögren’s Treatment
Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in Sjögren’s disease, the pharma reported at the American College of Rheumatology Convergence congress on Wednesday.
October 29, 2025
 · 
3 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS